サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1428047

トキソプラズマ症治療薬の世界市場レポート 2024

Toxoplasmosis Treatment Drugs Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
トキソプラズマ症治療薬の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

トキソプラズマ症治療薬の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には5.6%の年間複合成長率（CAGR）で41億8,000万米ドルに成長すると予想されます。予測期間に予想される拡大は、研究開発への投資、トキソプラズマ症治療法の登場、ヘルスケア支出の増加、感染症制御のための世界の取り組み、個別化医療アプローチの採用によるものと考えられます。予測期間中の注目すべき動向には、併用療法の開発、精密医療の治療戦略への統合、早期診断と介入への焦点、個別化された治療計画、ドラッグデリバリー方法の進歩が含まれます。

トキソプラズマ症感染症の有病率の予想される増加により、トキソプラズマ症治療薬市場の成長が促進される見込みです。トキソプラズマ症は、人間と動物の両方に寄生原虫トキソプラズマ・ゴンディによって引き起こされる感染症と疾患を含む用語であり、治療にはピリメタミン、スピラマイシン、ロイコボリンなどの薬剤が必要です。 2021年8月に疾病管理予防センターが報告したように、トキソプラズマ症感染症、特に先天性タイプのトキソプラズマ症感染症の急増は、世界の年間発生者数が19万100人と推定されており、トキソプラズマ症治療薬市場の拡大に貢献しています。発生率は出生1,000人あたり1.5人で、年間120万病気調整生存年（DALY）の疾病負担となります。

高齢者人口の増加は、トキソプラズマ症治療薬市場の重要な推進力になると予想されます。高齢者の医療である老年医学では、この年齢カテゴリーを正確に定義することが課題です。高齢者集団におけるトキソプラズマ症に効果的に対処するには、個別の治療計画、新薬、治療法の調査、予防への重点を通じて有効性と安全性のバランスをとった包括的なアプローチが必要です。注目すべきことに、2022年10月の世界貿易機関のデータは、2020年から2021年の間に60歳以上の人口が10億人から14億人に増加することを明らかにしました。予測によると、世界の60歳以上の成人人口は、2020年までに21億人に倍増します。 2050年には80歳以上の人口が3倍の4億2,600万人に達すると予想されています。したがって、高齢者人口の増加は、トキソプラズマ症治療薬市場の成長を推進する重要な要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界のトキソプラズマ症治療薬市場促進要因と抑制要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界のトキソプラズマ症治療薬の市場規模実績と成長、2018年から2023年
  • 世界のトキソプラズマ症治療薬市場規模と成長予測、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のトキソプラズマ症治療薬市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ピリメタミン
  • スピラマイシン
  • ロイコボリン
  • スルファジアジン
  • 葉酸
  • その他の薬物クラス
  • 世界のトキソプラズマ症治療薬市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 慢性トキソプラズマ症感染症
  • 急性トキソプラズマ感染症
  • 世界のトキソプラズマ症治療薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 非経口
  • 経口
  • 世界のトキソプラズマ症治療薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • オンライン薬局
  • 小売薬局

第7章 地域および国の分析

  • 世界のトキソプラズマ症治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のトキソプラズマ症治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • トキソプラズマ症治療薬市場の競合情勢
  • トキソプラズマ症治療薬市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson
    • F. Hoffmann-La Roche AG
    • Roche Holding AG
    • Merck &Co. Inc.

第31章 その他の大手および革新的な企業

  • AbbVie Inc.
  • Bayer AG
  • Novartis AG
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Otsuka Pharmaceutical Co. Ltd.
  • Baxter International Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan NV
  • AstraZeneca plc
  • Astellas Pharma Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13891

Toxoplasmosis treatment drugs are pharmaceutical products or medications designed to manage infectious diseases caused by Toxoplasma gondii. These drugs are utilized to treat parasitic infections resulting from exposure to a common parasite found in cat feces and contaminated food.

The primary types of drug classes in the toxoplasmosis treatment drugs market include pyrimethamine, spiramycin, leucovorin, sulfadiazine, folic acid, and other variations. Chronic toxoplasmosis infection refers to a prolonged infection caused by the protozoan parasite Toxoplasma gondii. Indications for these drugs include both chronic toxoplasmosis infection and acute toxoplasmosis infection. The administration of these drugs can be through parenteral or oral routes and distribution occurs through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

The toxoplasmosis treatment drugs market research report is one of a series of new reports from The Business Research Company that provides toxoplasmosis treatment drugs market statistics, including toxoplasmosis treatment drugs industry global market size, regional shares, competitors with a toxoplasmosis treatment drugs market share, detailed toxoplasmosis treatment drugs market segments, market trends and opportunities, and any further data you may need to thrive in the toxoplasmosis treatment drugs industry. This toxoplasmosis treatment drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The toxoplasmosis treatment drugs market size has grown strongly in recent years. It will grow from $3.16 billion in 2023 to $3.36 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The historical period's expansion can be ascribed to restricted treatment alternatives, heightened awareness of toxoplasmosis, a rising incidence of toxoplasmosis, the development of healthcare infrastructure, and changes in the regulatory environment.

The toxoplasmosis treatment drugs market size is expected to see strong growth in the next few years. It will grow to $4.18 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The expansion anticipated in the forecast period can be credited to investments in research and development, the emergence of therapies for toxoplasmosis, a rise in healthcare spending, worldwide initiatives for controlling infectious diseases, and the adoption of personalized medicine approaches. Notable trends during the forecast period encompass the development of combination drug therapies, the integration of precision medicine into treatment strategies, a focus on early diagnosis and intervention, personalized treatment regimens, and advancements in drug delivery methods.

The anticipated rise in the prevalence of toxoplasmosis infections is poised to drive the growth of the market for drugs treating toxoplasmosis. Toxoplasmosis, a term encompassing infection and illness caused by the protozoan parasite Toxoplasma gondii in both humans and animals, necessitates drugs such as pyrimethamine, spiramycin, and leucovorin for treatment. This surge in toxoplasmosis infections, particularly the congenital type, as reported by the Centers for Disease Control and Prevention in August 2021, with an estimated global incidence of 190,100 cases per year, contributes to the expansion of the toxoplasmosis treatment drug market. The incidence rate is 1.5 cases per 1,000 live births, with a disease burden of 1.2 million disease-adjusted life years (DALYs) annually.

The growing elderly population is expected to be a significant driver of the toxoplasmosis treatment drug market. Geriatrics, the medical care of older individuals, poses challenges in defining this age category accurately. Effectively addressing toxoplasmosis in the geriatric population requires a comprehensive approach, balancing efficacy and safety through personalized treatment plans, research into new drugs, therapeutic methods, and a focus on prevention. Notably, data from the World Trade Organization in October 2022 revealed an increase in the population aged 60 and above from 1 billion to 1.4 billion between 2020 and 2021. Projections indicate a doubling of the world's population of adults aged 60 and above to 2.1 billion by 2050, with the number of people aged 80 or more expected to triple, reaching 426 million. Consequently, the rising geriatric population is a significant factor propelling the growth of the toxoplasmosis treatment drug market.

Innovation in product offerings emerges as a prominent trend in toxoplasmosis treatment drugs. Leading companies in the market are actively developing advanced products to maintain their market position. An example of this trend is Meitheal Pharmaceuticals, a US-based pharmaceutical company, which, in September 2023, introduced Leucovorin Calcium for Injection in five different forms. These forms include single-dose vials containing 50 mg, 100 mg, 200 mg, 350 mg, and 500 mg. The intended use of leucovorin calcium for injection is in conjunction with high-dose methotrexate therapy for osteosarcoma.

Strategic investments are a key focus for major players in the toxoplasmosis treatment drug market. Such investments are made with a long-term objective, such as gaining a competitive edge, entering new markets, or developing innovative technologies. For instance, ASTRA Therapeutics, a UK-based drug development company, secured funding of CHF 150,000 ($173,787.15) in April 2023. This investment is earmarked for the development of therapies addressing parasite diseases such as malaria, cryptosporidiosis, and toxoplasmosis, which adversely affect millions of people globally and result in significant disease and productivity losses in cattle and agriculture.

In August 2023, Vyera Pharmaceuticals, LLC, a Switzerland-based pharmaceutical company, engaged in an asset purchase agreement with Phoenixus AG, a Swiss-based biopharmaceutical company. Through this agreement, both companies aim to sell the rights to Daraprim, a prescription drug containing pyrimethamine used for treating toxoplasmosis when combined with a sulfonamide, and Vecamyl, used to treat moderately severe to severe essential hypertension, as well as simple cases of malignant hypertension.

Major companies operating in the toxoplasmosis treatment drugs market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., AstraZeneca PLC, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals Inc., Lupin Ltd., Alvogen Group Inc., Manus Aktteva Biopharma LLP

North America was the largest region in the toxoplasmosis treatment drugs market in 2023. The regions covered in the toxoplasmosis treatment drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the toxoplasmosis treatment drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The toxoplasmosis treatment drug market consists of sales of clindamycin and atovaquone. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Toxoplasmosis Treatment Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on toxoplasmosis treatment drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for toxoplasmosis treatment drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The toxoplasmosis treatment drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug Class: Pyrimethamine; Spiramycin; Leucovorin; Sulfadiazine; Folic Acid; Other Drug Class
  • 2) By Indication: Chronic Toxoplasmosis Infection; Acute Toxoplasmosis Infection
  • 3) By Route of Administration: Parenteral; Oral
  • 4) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Roche Holding AG; Merck & Co. Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Toxoplasmosis Treatment Drugs Market Characteristics

3. Toxoplasmosis Treatment Drugs Market Trends And Strategies

4. Toxoplasmosis Treatment Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Toxoplasmosis Treatment Drugs Market Size and Growth

  • 5.1. Global Toxoplasmosis Treatment Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Toxoplasmosis Treatment Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Toxoplasmosis Treatment Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Toxoplasmosis Treatment Drugs Market Segmentation

  • 6.1. Global Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pyrimethamine
  • Spiramycin
  • Leucovorin
  • Sulfadiazine
  • Folic Acid
  • Other Drug Class
  • 6.2. Global Toxoplasmosis Treatment Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chronic Toxoplasmosis Infection
  • Acute Toxoplasmosis Infection
  • 6.3. Global Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Parenteral
  • Oral
  • 6.4. Global Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

7. Toxoplasmosis Treatment Drugs Market Regional And Country Analysis

  • 7.1. Global Toxoplasmosis Treatment Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Toxoplasmosis Treatment Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Toxoplasmosis Treatment Drugs Market

  • 8.1. Asia-Pacific Toxoplasmosis Treatment Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Toxoplasmosis Treatment Drugs Market

  • 9.1. China Toxoplasmosis Treatment Drugs Market Overview
  • 9.2. China Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Toxoplasmosis Treatment Drugs Market

  • 10.1. India Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Toxoplasmosis Treatment Drugs Market

  • 11.1. Japan Toxoplasmosis Treatment Drugs Market Overview
  • 11.2. Japan Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Toxoplasmosis Treatment Drugs Market

  • 12.1. Australia Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Toxoplasmosis Treatment Drugs Market

  • 13.1. Indonesia Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Toxoplasmosis Treatment Drugs Market

  • 14.1. South Korea Toxoplasmosis Treatment Drugs Market Overview
  • 14.2. South Korea Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Toxoplasmosis Treatment Drugs Market

  • 15.1. Western Europe Toxoplasmosis Treatment Drugs Market Overview
  • 15.2. Western Europe Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Toxoplasmosis Treatment Drugs Market

  • 16.1. UK Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Toxoplasmosis Treatment Drugs Market

  • 17.1. Germany Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Toxoplasmosis Treatment Drugs Market

  • 18.1. France Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Toxoplasmosis Treatment Drugs Market

  • 19.1. Italy Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Toxoplasmosis Treatment Drugs Market

  • 20.1. Spain Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Toxoplasmosis Treatment Drugs Market

  • 21.1. Eastern Europe Toxoplasmosis Treatment Drugs Market Overview
  • 21.2. Eastern Europe Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Toxoplasmosis Treatment Drugs Market

  • 22.1. Russia Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Toxoplasmosis Treatment Drugs Market

  • 23.1. North America Toxoplasmosis Treatment Drugs Market Overview
  • 23.2. North America Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Toxoplasmosis Treatment Drugs Market

  • 24.1. USA Toxoplasmosis Treatment Drugs Market Overview
  • 24.2. USA Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Toxoplasmosis Treatment Drugs Market

  • 25.1. Canada Toxoplasmosis Treatment Drugs Market Overview
  • 25.2. Canada Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Toxoplasmosis Treatment Drugs Market

  • 26.1. South America Toxoplasmosis Treatment Drugs Market Overview
  • 26.2. South America Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Toxoplasmosis Treatment Drugs Market

  • 27.1. Brazil Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Toxoplasmosis Treatment Drugs Market

  • 28.1. Middle East Toxoplasmosis Treatment Drugs Market Overview
  • 28.2. Middle East Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Toxoplasmosis Treatment Drugs Market

  • 29.1. Africa Toxoplasmosis Treatment Drugs Market Overview
  • 29.2. Africa Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Toxoplasmosis Treatment Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Toxoplasmosis Treatment Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Toxoplasmosis Treatment Drugs Market Competitive Landscape
  • 30.2. Toxoplasmosis Treatment Drugs Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Roche Holding AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Merck & Co. Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Toxoplasmosis Treatment Drugs Market Other Major And Innovative Companies

  • 31.1. AbbVie Inc.
  • 31.2. Bayer AG
  • 31.3. Novartis AG
  • 31.4. Sanofi S.A.
  • 31.5. Bristol-Myers Squibb Company
  • 31.6. GlaxoSmithKline plc
  • 31.7. Takeda Pharmaceutical Company Limited
  • 31.8. Eli Lilly and Company
  • 31.9. Boehringer Ingelheim International GmbH
  • 31.10. Otsuka Pharmaceutical Co. Ltd.
  • 31.11. Baxter International Inc.
  • 31.12. Teva Pharmaceutical Industries Ltd.
  • 31.13. Mylan N.V.
  • 31.14. AstraZeneca plc
  • 31.15. Astellas Pharma Inc.

32. Global Toxoplasmosis Treatment Drugs Market Competitive Benchmarking

33. Global Toxoplasmosis Treatment Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Toxoplasmosis Treatment Drugs Market

35. Toxoplasmosis Treatment Drugs Market Future Outlook and Potential Analysis

  • 35.1 Toxoplasmosis Treatment Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Toxoplasmosis Treatment Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Toxoplasmosis Treatment Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer